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Abstract
Background
Adopting a healthy lifestyle is associated with prolonged life expectancy. The main modifi-
able lifestyle-related risk factors are hazardous alcohol drinking, smoking, excess body
weight and lack of physical activity. Our aim was to estimate the impact of unfavourable life-
style factors on abnormalities in laboratory tests reflecting liver status, inflammation and
lipid metabolism in a population-based cross-sectional study.
Methods
The study included 22,273 participants (10,561 men, 11,712 women) aged 25–74 years
from the National FINRISK Study. Data on alcohol use, smoking, body weight, and physical
activity were recorded from structured interviews. The risk scores for the various life style
factors were established on a 0–8 scale and used to stratify the population in classes to
allow estimates of their joint effects. Serum liver enzymes (GGT, ALT), C-reactive protein
(CRP) and lipid profiles were measured using standard laboratory techniques.
Results
Consistent dose-response relationships were observed between the number of unfavour-
able risk factors and serum levels of GGT, ALT, CRP, cholesterol, HDL, LDL and triglycer-
ides (p < 0.0005 for linear trend in all comparisons). When compared with those with zero
risk factors, the multivariable-adjusted odds ratios (ORs) for abnormalities in all biomarkers
were significantly higher in those with a sum of risk score two or more. The most striking
increases in ORs in the group with the highest numbers of risk factors were observed
among men in serum GGT: 26.6 (12.4–57.0), ALT: 40.3 (5.3–307.8), CRP: 16.2 (7.8–33.7)
and serum triglycerides: 14.4 (8.6–24.0).
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Conclusions
The data support the view that the presence of unfavourable life style risk factors is associ-
ated with distinct abnormalities in laboratory tests for liver function, inflammation and lipid
status. Such biomarkers may prove to be of value in the assessment of interventions aimed
at reducing unfavourable risk factors and in helping individuals in long-term maintenance of
lifestyle modifications.
Introduction
Heavy alcohol drinking, smoking, excess body weight and lack of physical exercise are com-
mon modifiable risk factors of lifestyle, which may all contribute to the incidence of chronic
diseases and premature death [1–5]. There may also be synergistic and additive interactions
between such factors in individuals with clustering of unfavourable lifestyle factors [3, 4, 6].
Therefore, interventions aimed at reducing the number of risk factors has been recognized as
an important target in both personalized medicine and public health policies [7]. Recent stud-
ies have estimated that adopting a healthy lifestyle even at the age of 50 could add more than a
decade to life suggesting significant therapeutic potential for lifestyle interventions [3, 8].
A large body of evidence indicates that the occurrence of increased gamma-glutamyltrans-
ferase (GGT), and alanine aminotransferase (ALT) enzyme activities in apparently healthy
individuals may often be attributed to unhealthy lifestyle factors, such as alcohol consumption
or excess body weight [9–13]. The increases in these liver enzymes may also associate with
extra-hepatic disease risks, including metabolic syndrome, and cardio- or cerebrovascular
events [13–15]. While the biochemical pathways underlying such observations have remained
unclear, previous findings have suggested that inflammatory processes [16–18], oxidative
stress [19, 20] and generation of abnormal lipid profiles [21] are key pathogenic factors in the
sequence of events leading to hepatotoxicity [22] or other adverse health effects, such as inci-
dent stroke [5], in individuals presenting with various clusters of risk factors.
So far, only few studies have been available to examine the individual and joint impacts of
the various unfavourable life style factors on biochemical indices of health. Considering this
issue, we aimed to investigate the combined effects of various lifestyle-related factors on bio-
markers of liver status (ALT, GGT), inflammation (C-reactive protein) and lipid metabolism
(cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides) in a large national FINRISK
population-based study, which includes detailed records on alcohol consumption, smoking,
physical activity and health status. It is assumed that further understanding of the biomarker
behaviour in response to various types of unhealthy behaviours may improve our possibilities
for interventions aimed at adopting more favourable lifestyles.
Materials and methods
Study design, data sources and participants
The study collects extensive data from a cross-sectional population health survey (The
National FINRISK Study) carried out in Finland in 1997, 2002 and 2007. In each survey year
an age- and gender stratified random sample was drawn from the population register accord-
ing to an international protocol [23]. Clinical examinations included physical measurements,
laboratory tests and detailed questionnaires gathering information on current health status,
alcohol intake, diet, smoking, physical activity, medical history and socioeconomic factors [23,
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24]. Body weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively.
Body mass index (BMI, kg/m2) was calculated as a measure of relative body weight. The data
was available from 22,273 apparently healthy individuals: 10,561 men and 11,712 women
(mean age 49 ± 13 years, range 25–74 years) who completed the questionnaires and attended
the medical examination. The study excluded individuals with any apparent clinical signs of
liver disease, ischaemic heart or brain disease or active infection at the time of blood sampling.
The questionnaire used here for registering information on health and lifestyle has been
previously developed and validated for use in international population-based health surveys
[23–25]. The responses to each question on alcohol consumption, smoking, physical activity
and coffee consumption are assigned to mutually exclusive and collectively exhaustive catego-
ries [25]. Data on alcohol consumption was registered from the past 12 months prior to blood
sampling and included information on the types of beverages consumed as well as the amounts
and frequencies of consumption. The ethanol content in different beverages was quantitated
in grams of ethanol based on defined portion sizes as follows: regular beer 12 grams (1/3 L),
strong beer 15.5 grams (1/3 L), long drink 15.5 grams (1/3 L), spirit 12 grams (4 cL), wine 12
grams (12 cL) and cider 12 grams (1/3 L). Information on smoking habits was collected with a
set of standardized questions and the data was expressed as the amounts of cigarettes per day.
Habitual physical activity including both the number and total time used for physical exercises
were also registered from each participant. Coffee consumption was assessed with a set of stan-
dardized questions and expressed as the intake of standard servings of coffee (cups) per day.
The data obtained from the questionnaires was subsequently used to define scores for low
risk (= 0), medium risk (= 1) and high risk (= 2) categories for each individual risk factor fol-
lowing recent work on health-related risk assessment in relation to alcohol consumption,
smoking, BMI status and physical activity [3, 8, 26–28]. In this work, the variables were, how-
ever, categorized into three ordinal levels to yield increased statistical power as compared to
previously used dichotomous classification [3]. For alcohol consumption the scores were
defined as follows: 0 = no consumption; 1 = alcohol consumption between 1–14 (men) or 1–7
(women) standard drinks per week; 2 = alcohol consumption exceeding 14 drinks (men) or 7
drinks (women) per week. For smoking 0 = no smoking, 1 = 1–19 cigarettes per day, 2 =� 20
cigarettes per day; for BMI 0 = BMI < 25; 1 = BMI� 25 and< 30; 2 = BMI� 30. For physical
activity 0 represents those with physical activity over 4 hours per week; 1 = those with physical
activity between 0.5 and 4 hours per week and 2 = those with physical activity less than 30
min/week. The sum of these scores provided a total number of risk factors, with higher scores
(maximum = 8) indicating an unhealthier lifestyle.
The approval for the data collection was received from the Coordinating Ethics Committee
of the Helsinki and Uusimaa Hospital District in 2002 and 2007 and from the Ethics Commit-
tee of the National Public Health Institute in 1997. All surveys were conducted in accordance
with the Declaration of Helsinki according to the ethical rules of the National Public Health
Institute.
Laboratory analyses
Serum liver enzymes (ALT and GGT) were measured by standard clinical chemical methods
on an Abbott Architect clinical chemistry analyzer following the recommendations of the
assay manufacturer (Abbott Laboratories, Abbott Park, IL, USA). High-sensitivity CRP, a bio-
marker of inflammation, was determined using a latex immunoassay (Sentinel Diagnostics,
Milan, Italy) with the Abbott Architect c8000 clinical chemistry analyzer. Lipid profiles
included determinations of total cholesterol, high-density lipoprotein-associated cholesterol
(HDL), low-density lipoprotein (LDL) and total triglycerides using standard enzymatic
Laboratory tests and lifestyle
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methods. All laboratory tests were subjects to continuous external quality control programs
organized by Labquality, Finland and CDC (Center for Disease Control and Prevention) qual-
ity assurance and standardization program for serum lipids. The cut-offs for the normal limits
of the different markers were as follows: ALT (50 U/L men; 35 U/L women), GGT (60 U/L
men; 40 U/L women), CRP (3.0 mg/L), cholesterol (5 mmol/L), HDL cholesterol (1.0 mmol/L
men, 1.2 mmol/L women), LDL cholesterol (3.0 mmol/L), triglycerides (1.7 mmol/L).
Statistical methods
The main characteristics were examined using analysis of variance (ANOVA) with polynomial
contrasts to reveal possible trends across increasing risk score categories. The distribution of
abnormal biomarker levels across the risk categories were analysed by chi-square test for
trend. Binary logistic regression was used to estimate the odds ratios (ORs) of abnormal bio-
marker levels associated with the risk score categories, adjusting for age and coffee consump-
tion, as these factors are known to potentially associate with abnormal biomarker levels and
showed association in univariate analysis. All factors were entered simultaneously into the
multivariable model. Potential multicollinearity among the covariates was examined by calcu-
lating the Variance Inflation Factor (VIF) and no evidence was found. Correlations between
the risk scores and various biomarkers were calculated using Spearman’s rank correlation
coefficients. The analyses were carried out with IBM SPSS Statistics 24.0 (Armonk, NY: IBM
Corp.). A p-value< 0.05 was considered statistically significant.
Results
The main demographic characteristics of the participants classified to subgroups according to
the distribution of unfavourable lifestyle risk factor scores and gender are summarized in
Table 1. Higher levels of alcohol consumption, increased body weight, smoking and physical
inactivity were found to characterize the individuals with high risk scores. Age of the partici-
pants showed a quadratic association between the risk scores such that the highest mean ages
were noted in the middle portion of the risk score categories (p< 0.0005 for both genders).
Coffee consumption was found to increase with increasing number of risk factor scores in
both men and women (p< 0.0005 for linear trend in both genders).
Fig 1 demonstrates the median and interquartile ranges for the various biomarkers in
groups with different risk factor status. Consistent dose-response relationships were observed
between the number of unfavourable risk factors and biomarker levels in all biomarkers. The
frequencies of values exceeding the upper normal limits for GGT, ALT, CRP and triglycerides
or deviations from the target ranges for serum lipids in the different subgroups are summa-
rized in Table 2. The occurrence of abnormal findings in each laboratory parameter was found
to increase in a rather linear and significant manner as a function of the risk score status
(p< 0.0005 for all comparisons).
Table 3 summarizes the multivariable relative risks of abnormal biomarker findings accord-
ing to different risk categories. The biomarkers of liver status, inflammation and lipid profiles
were all found to react to life-style associated risk factors in a sensitive manner and to show sig-
nificant associations with the number of risk scores when compared with participants with
zero risk factors. The most striking increases in ORs in the group with the highest numbers of
risk factors were observed for men in serum GGT: 26.6 (12.4–57.0), ALT: 40.3 (5.3–307.8),
CRP: 16.2 (7.8–33.7) and serum triglycerides: 14.4 (8.6–24.0). When using BMI as a covariate
in the binary logistic regression analyses, similar findings on ORs for abnormal biomarker sta-
tus were observed, except for the lack of significance for HDL cholesterol in men and for
HDL-, LDL- and total cholesterol in women (data not shown).
Laboratory tests and lifestyle
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The strongest correlations between the numbers of various unfavourable risk factors and
laboratory tests were observed for serum GGT (rs = 0.381 for men; rs = 0.311 for women); ALT
(rs = 0.252 for men; rs = 0.166 for women), CRP (rs = 0.308 for men; rs = 0.293 for women) and
serum triglycerides (rs = 0.274 for men, rs = 0.258 for women (p< 0.0001 for all comparisons).
Discussion
The present cross-sectional observational study among a large population-based sample of
individuals indicate that unfavourable lifestyle factors increase the risk for abnormalities in
biomarkers for liver status, inflammation and lipid profiles in a rather linear and significant
manner, which supports the view that profound health benefits could be achieved following
the habits of a healthy lifestyle. According to recent observations adherence to favourable life-
style factors significantly prolongs residual life expectancy [3] and reduces the burden of vari-
ous chronic diseases [5, 26, 27]. Our data further indicates that laboratory parameters could be
used as tools in patient advice and guidance during interventions aimed at achieving a more
favourable lifestyle. The biomarkers chosen for the present comparisons appear to be sensitive
indicators of adverse biomedical effects related to lifestyle and could therefore also be used in
the follow-up of individual patients for long-term maintenance of lifestyle modifications.
Recent findings in lifestyle medicine have indicated that the main determinants for adopt-
ing a healthy life style include alcohol drinking in moderation, weight control, not smoking,
and taking regular exercise [3, 6, 26, 27]. These studies have also emphasized the benefits of
avoiding combinations of unfavourable risk factors, which is also in accordance with the pres-
ent findings using biomarker levels as outcome measures. Previous studies on alcohol con-
sumption as an individual lifestyle risk factor have recently concluded that regular alcohol
Table 1. Main characteristics of the participants, as classified according to lifestyle risk factor scores.
Men
Risk score 0 1 2 3 4 5 6 7–8
n (%) 217 (2.1) 1131 (10.7) 2321 (22.0) 2737 (25.9) 2181 (20.7) 1213 (11.5) 563 (5.3) 198 (1.9)
Age, years, mean ± SD 44.1 ± 14.3 47.5 ± 14.3 50.0 ± 14.3 51.2 ± 13.5 50.1 ± 13.2 49.3 ± 12.2 47.9 ± 11.7 47.4 ± 10.4
Alcohol consumption, g/day 0.0 ± 0.0 4.4 ± 6.3 6.9 ± 8.8 10.2 ± 13.0 15.3 ± 17.6 22.9 ± 25.1 33.0 ± 30.0 41.9 ± 29.8
BMI 23.1 ± 1.4 24.1 ± 2.1 25.6 ± 2.8 27.2 ± 3.3 28.6 ± 4.4 29.3 ± 4.7 29.7 ± 5.1 31.7 ± 4.1
Waist circumference, cm 82.8 ± 5.7 86.9 ± 7.0 91.3 ± 8.7 96.2 ± 9.9 100.1 ± 12.2 102.1 ± 12.6 103.1 ± 13.2 108.4 ± 11.1
Smoking, cigarettes/day 0.0 ± 0.0 0.3 ± 1.8 1.0 ± 3.4 2.7 ± 6.2 5.8 ± 8.9 11.4 ± 11.0 18.2 ± 12.0 24.3 ± 9.4
Coffee, cups/day 3.6 ± 2.9 3.9 ± 2.7 4.0 ± 2.7 4.5 ± 3.0 5.0 ± 3.5 5.3 ± 3.6 5.7 ± 3.7 5.9 ± 4.4
Physical activity,
number of exercises per week
4.3 ± 2.6 3.5 ± 2.1 2.9 ± 2.0 2.4 ± 2.0 2.0 ± 2.2 1.4 ± 1.7 1.3 ± 2.1 0.9 ± 1.8
Women
Risk score 0 1 2 3 4 5 6 7–8
n (%) 447 (3.8) 1939 (16.6) 3183 (27.2) 3004 (25.6) 1945 (16.6) 816 (7.0) 297 (2.5) 81 (0.7)
Age, years, mean ± SD 41.5 ± 12.5 44.8 ± 13.4 47.8 ± 13.5 49.5 ± 13.2 49.9 ± 13.1 48.8 ± 12.2 47.5 ± 11.0 48.4 ± 11.4
Alcohol consumption, g/day 0.0 ± 0.0 1.9 ± 3.2 3.3 ± 5.0 4.6 ± 7.5 6.4 ± 8.0 12.3 ± 11.9 16.8 ± 15.2 22.8 ± 18.7
BMI 22.4 ± 1.6 23.0 ± 2.4 24.7 ± 3.3 27.4 ± 4.9 29.9 ± 5.7 30.7 ± 6.0 31.0 ± 5.7 33.3 ± 4.7
Waist circumference, cm 73.8 ± 5.8 75.7 ± 7.3 79.7 ± 9.1 86.3 ± 12.2 92.4 ± 14.0 94.6 ± 14.5 95.9 ± 14.0 102.1 ± 12.0
Smoking, cigarettes/day 0.0 ± 0.0 0.2 ± 1.2 0.9 ± 3.1 1.9 ± 4.6 3.6 ± 6.2 6.8 ± 8.3 14.6 ± 11.0 18.8 ± 6.7
Coffee, cups/day 3.1 ± 2.5 3.2 ± 2.4 3.5 ± 2.4 3.8 ± 2.4 4.0 ± 2.6 4.2 ± 2.9 4.9 ± 3.1 4.5 ± 2.9
Physical activity,
number of exercises per week
3.7 ± 1.8 3.2 ± 2.1 2.7 ± 2.1 2.4 ± 2.0 2.0 ± 2.0 1.7 ± 1.9 1.3 ± 2.0 0.8 ± 0.8
BMI, body mass index; n, number of observations
https://doi.org/10.1371/journal.pone.0218463.t001
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drinking in amounts exceeding 8 standard drinks per week would lower residual life expec-
tancy at the age of 40 years by 0.5 years, the levels of 30 drinks per week leading to a loss of 4–5
years [26–28]. In individuals with excess body weight even smaller levels of alcohol consump-
tion increase the relative risk of hepatotoxicity, as reflected in elevated liver enzyme activities,
fatty changes in the liver and increased rates of mortality due to liver cirrhosis [11, 12, 29]. Pre-
vious studies have also reported significant synergistic effect of smoking and alcohol use in
increasing liver enzyme activities [30, 31].
Based on current findings lifestyle intervention could be effective when treating patients
with liver problems [32–34]. However, the likelihood for a wide variety of other clinical condi-
tions, such as heart diseases, diabetes or cancer are also significantly driven by lifestyle [3, 8,
26, 27]. Typical pathophysiological characteristics associated with lifestyle and disease risks
seem to include chronic inflammation, oxidative stress and altered fatty acid metabolism [9,
18, 34]. Thus, it may be expected that systematic measurements of conventional biomarkers
reflecting liver status, inflammation and lipid profiles could also offer a significant contribu-
tion to the comprehensive assessment of such patients and help in elucidating the mechanisms
behind the adverse effects of various behavioural phenotypes. Previously, changes in liver
enzyme activities have been shown to be associated with both hepatic and extrahepatic disease
risks, including cardio- and cerebrovascular risks, deposition of triglycerides in tissues and the
Fig 1. Biomarkers of liver function, inflammation and lipid status in individuals with varying lifestyle risk factor status. The data for liver
enzymes (GGT, ALT), hs-CRP (biomarker for inflammation) and lipid profiles (cholesterol, HDL, LDL, triglycerides) are shown for both men and
women as medians and interquartile ranges. The box represents the middle 50% of the values and the whiskers go down to the 10th percentile and up
to the 90th. The scores for the individual risk factors were defined as follows: Alcohol consumption, 0 = no consumption; 1 = alcohol consumption
between 1–14 (men) or 1–7 (women) standard drinks per week; 2 = alcohol consumption exceeding 14 drinks (men) or 7 drinks (women) per week
Smoking, 0 = no smoking, 1 = 1–19 cigarettes per day, 2 =� 20 cigarettes per day BMI, 0 = BMI< 25; 1 = BMI� 25 and< 30; 2 =� 30 Physical
activity, 0 = physical activity over 4 hours per week; 1 = physical activity between 0.5 and 4 hours per week; 2 = physical activity less than 30 min per
week. The sum of the above scores provided a total number of risk factors, with higher scores (maximum = 8) indicating an unhealthier lifestyle.
https://doi.org/10.1371/journal.pone.0218463.g001
Table 2. The proportion (%) of abnormal biomarker findings in individuals classified according to the number of life-style associated risk factor scores.
Men
Risk score 0 1 2 3 4 5 6 7–8 pa
GGT� 60 U/L 3.7 5.8 8.2 14.7 20.8 29.2 38.2 49.5 < 0.0005
ALT� 50 U/L 1.4 2.8 6.0 11.3 14.7 18.8 25.3 31.8 < 0.0005
CRP-hs� 3 mg/L 4.2 8.9 13.3 16.0 22.0 28.0 33.8 42.1 < 0.0005
Cholesterol� 5 mmol/L 47.0 57.0 64.1 69.0 69.4 73.6 74.7 82.3 < 0.0005
HDL� 1 mmol/L 7.8 9.7 15.9 19.0 21.2 21.0 21.6 25.3 < 0.0005
LDL� 5 mmol/L 52.9 56.3 61.4 64.8 66.3 68.0 73.5 66.9 < 0.0005
Triglycerides� 1.7 mmol/L 12.0 16.8 25.7 35.6 41.4 47.8 50.3 65.7 < 0.0005
Women
Risk score 0 1 2 3 4 5 6 7–8 pa
GGT� 40 U/L 5.8 4.7 7.1 11.5 16.4 25.5 30.6 33.3 < 0.0005
ALT� 35 U/L 3.7 5.8 6.0 9.0 12.7 14.2 16.4 11.1 < 0.0005
CRP-hs� 3 mg/L 9.7 12.0 15.1 23.0 33.3 35.8 39.4 58.0 < 0.0005
Cholesterol� 5 mmol/L 54.9 56.9 62.5 67.1 68.9 67.5 67.0 76.5 < 0.0005
HDL� 1.2 mmol/L 6.3 8.9 12.0 16.4 22.1 23.4 20.1 30.0 < 0.0005
LDL� 5 mmol/L 44.5 47.3 53.5 58.8 60.7 60.3 59.9 71.2 < 0.0005
Triglycerides� 1.7 mmol/L 6.7 8.9 12.7 19.7 25.2 29.0 31.0 43.2 < 0.0005
a, p for linear trend
GGT, gamma-glutamyltransferase; ALT, alanine aminotransferase; CRP, C-reactive protein; HDL, high-density lipoproteins; LDL, low-density lipoprotein
https://doi.org/10.1371/journal.pone.0218463.t002
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Table 3. Odds ratios (ORs) for abnormal biomarker status according to individual lifestyle risk factor scores, as
adjusted for age and coffee consumption.
Men Women
Risk score OR (95% CI) OR (95% CI)
GGT 0
1 1.5 (0.7 to 3.1) 0.7 (0.4 to 1.1)
2 2.1 (1.0 to 4.4)a 1.0 (0.6 to 1.5)
3 4.2 (2.1 to 8.7)c 1.6 (1.1 to 2.4)a
4 6.7 (3.3 to 13.7)c 2.4 (1.6 to 3.7)c
5 10.5 (5.1 to 21.5)c 4.6 (3.0 to 7.1)c
6 16.6 (8.0 to 34.4)c 6.6 (4.1 to 10.6)c
7–8 26.6 (12.4 to 57.0)c 7.0 (3.8 to 13.1)c
ALT 0
1 2.1 (0.3 to 16.4) 1.6 (0.7 to 3.8)
2 5.0 (0.7 to 37.2) 1.6 (0.7 to 3.8)
3 11.3 (1.5 to 82.4)a 2.6 (1.1 to 6.0)a
4 15.6 (2.1 to 114.4)b 3.8 (1.6 to 8.8)b
5 20.8 (2.8 to 153.0)b 4.4 (1.8 to 10.4)b
6 30.0 (4.0 to 222.4)b 5.4 (2.1 to 14.1)c
7–8 40.3 (5.3 to 307.8)c 3.5 (0.8 to 15.0)
CRP 0
1 2.0 (1.0 to 4.0) 1.2 (0.9 to 1.8)
2 3.0 (1.5 to 5.8)b 1.6 (1.2 to 2.3)b
3 3.6 (1.8 to 7.1)c 2.7 (2.0 to 3.8)c
4 5.6 (2.8 to 11.0)c 4.7 (3.3 to 6.5)c
5 7.9 (4.0 to 15.7)c 5.4 (3.8 to 7.6)c
6 11.1 (5.5 to 22.2)c 6.6 (4.4 to 9.8)c
7–8 16.2 (7.8 to 33.7)c 13.7 (7.9 to 23.7)c
Chol 0
1 1.4 (1.0 to 1.9)a 0.9 (0.7 to 1.1)
2 1.8 (1.4 to 2.4)c 1.0 (0.8 to 1.2)
3 2.1 (1.6 to 2.8)c 1.1 (0.9 to 1.4)
4 2.2 (1.7 to 3.0)c 1.2 (1.0 to 1.5)
5 2.8 (2.1 to 3.8)c 1.2 (0.9 to 1.5)
6 3.0 (2.1 to 4.2)c 1.2 (0.9 to 1.7)
7–8 4.9 (3.1 to 7.8)c 1.9 (1.1 to 3.4)a
HDL 0
1 1.3 (0.7 to 2.1) 1.5 (1.0 to 2.3)
2 2.2 (1.3 to 3.6)b 2.1 (1.4 to 3.1)c
3 2.7 (1.7 to 4.5)c 2.9 (2.0 to 4.4)c
4 3.2 (1.9 to 5.3)c 4.2 (2.8 to 6.4)c
5 3.2 (1.9 to 5.3)c 4.7 (3.0 to 7.1)c
6 3.3 (1.9 to 5.7)c 3.9 (2.4 to 6.4)c
7–8 4.1 (2.3 to 7.5)c 6.6 (3.5 to 12.2)c
LDL 0
1 1.1 (0.8 to 1.6) 1.0 (0.7 to 1.3)
2 1.4 (1.0 to 1.9) 1.1 (0.9 to 1.4)
3 1.5 (1.1 to 2.2)a 1.3 (1.0 to 1.7)a
4 1.6 (1.2 to 2.3)b 1.4 (1.1 to 1.9)b
(Continued)
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development of insulin resistance [10, 15, 35, 36]. Based on the present analysis which
excluded individuals with clinically apparent diseases at the time of the study the biomarker
responses appear to represent early changes in the sequence of events leading from risk expo-
sure to possible disease outcomes. It should further be noted that in this material similar con-
clusions on a significant linear relationships between the sum of lifestyle risk factors and
current biomarker levels were also reached by further exclusions of individuals with any previ-
ous history of cardiac or cerebrovascular diseases, chronic inflammatory diseases, diabetes or
abnormal oral glucose test (data not shown).
Previous studies have suggested possible mechanistic links between hepatic and extrahe-
patic disease outcomes, as supported by findings indicating that GGT enzyme is able to fuel
LDL oxidation in coronary plaques [37]. In accordance with this view, alcohol and its reactive
metabolites are known to exert toxic effects virtually in all tissues and even relatively low levels
of chronic drinking may increase the risk for carcinogenesis [38–40], cognitive decline [41,
42], cardiac dysfunction [43–45] and all-cause mortality [28, 46], which may also associate
with abnormalities in blood lipid profiles and indices of inflammation [47–49]. Based on the
present data abnormalities in serum CRP, a widely used clinical biomarker of inflammation,
and lipid profiles appear to follow the burden of unfavourable risk factors and abnormalities in
markers of liver function in a sensitive manner. Although CRP alone may be considered as a
relatively unspecific biomarker of inflammation, previous studies have shown that CRP levels
predict cardiovascular events even in individuals without any atherosclerotic manifestations or
conventional risk factors [50, 51]. Evidence also suggests that CRP is an important regulator of
inflammatory processes [51].
Physical inactivity and sedentary behaviour are typical characteristics of an unhealthy life-
style and increasingly common causes of health problems across the world [3, 6, 32, 52–55].
The present biomarker-based data also underscores the benefits of physical activity as an inde-
pendent and significant part of a favourable lifestyle. The individuals engaged in moderate or
vigorous physical activity show significantly lower risks for biomarker abnormalities than the
corresponding groups of those with low or sedentary activity even in the presence of other risk
factors. The data also supports the view that physical exercise could also be used as a
Table 3. (Continued)
Men Women
Risk score OR (95% CI) OR (95% CI)
5 1.8 (1.3 to 2.6)b 1.4 (1.1 to 1.9)a
6 2.3 (1.5 to 3.4)c 1.4 (1.0 to 2.1)
7–8 1.7 (1.1 to 2.9)a 2.5 (1.3 to 4.8)b
Trigl 0
1 1.5 (0.9 to 2.3) 1.2 (0.8 to 1.8)
2 2.5 (1.6 to 3.8)c 1.6 (1.1 to 2.4)a
3 3.9 (2.6 to 6.0)c 2.7 (1.8 to 4.0)c
4 5.1 (3.3 to 7.9)c 3.8 (2.5 to 5.5)c
5 6.7 (4.4 to 10.4)c 4.8 (3.2 to 7.3)c
6 7.6 (4.8 to 11.9)c 5.8 (3.7 to 9.2)c
7–8 14.4 (8.6 to 24.0)c 9.7 (5.4 to 17.4)c
a, p< 0.05
b, p< 0.01
c, p< 0.001. For abbreviations, see Table 2.
https://doi.org/10.1371/journal.pone.0218463.t003
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therapeutic approach to counteract life-style associated adverse metabolic and obesogenic
effects and possibly confer long-term benefits to lifestyle-associated disease burden in general
[54, 56–58]. Previously, moderate to vigorous physical activity was found to improve the
degree of hepatic steatosis in fatty liver disease through reducing inflammation and oxidative
stress and altering lipid metabolism even in the absence of any detectable weight reduction
[34]. Interestingly, recent UK biobank based study has also concluded that physically active
individuals have longer life expectancies across the different levels and indices of adiposity
than those with low levels of activity [58].
Based on current data the biomarker responses to factors of lifestyle seem to be significantly
driven by their joint effects. However, it should be emphasized that there may also be other
types of unhealthy behaviours, such as particular dietary patterns, which may contribute to
adverse health effects [3, 8, 26, 27]. Unfortunately, in this work we did not have sufficient
information available on the exact compositions of the diet. Here the unfavourable lifestyle fac-
tors were, however, found to be associated with an increasing trend of coffee consumption in
the high risk subgroups, which is in accordance with previous observations indicating that
heavy smoking may be related with increased coffee intake [59]. Interestingly, coffee consump-
tion has been previously shown to be associated with a reduced risk for both all-cause and
cause-specific mortality [60]. Lower levels of liver-derived enzymes have also been found to
occur in alcohol consumers with high levels of coffee consumption when compared to those
with no coffee consumption suggesting possible hepatoprotective effects of coffee intake [12,
60].
Previous work has also emphasized the role of high-fat diets in aggravating inflammation,
oxidative stress and metabolic aberrations [18–20]. High carbohydrate and processed/red
meat consumption together with insufficient vegetable, fruit or vitamin intake are other
important dietary components which may associate with adverse metabolic and hepatic effects
[18, 26, 27, 32, 61]. Thus, the individual assessment of health risks should include consider-
ations of the quality of the diet which may include several synergistic triggers for adverse
health effects, as also previously reported from both experimental animal models [20] and
human studies [12, 13, 18, 62–67]. In real life situations simultaneous adherence to several
low-risk lifestyle-related factors may, however, be difficult. Thus, there is an obvious need for
improved national health policies emphasizing tools for health care outcome measurements.
The present findings suggest a possible expanded role for clinical laboratory information in
the follow-up of patients presenting with unfavourable lifestyle risk factors.
Following previous work on lifestyle factors and health risks [3], we used BMI here as a part
of the risk factor scoring system instead of using it as a covariate. This may be justified to pre-
vent over-adjustment due to controlling for a variable which may be on a causal pathway
between exposure and outcome. In this work the lack of information on the quality of the diet
may further support the choice of using BMI as part of the lifestyle-related index. This
approach was also supported by additional analyses using BMI as a covariate where similar
conclusions were also reached on a linear relationships between the sum of lifestyle risk factors
and biomarker levels, except for a lack of significance for HDL-cholesterol in men and for
HDL-, LDL- and total cholesterol in women.
The strengths of this study include the large number of study subjects and a comprehensive
assessment of various lifestyle risk factors together with several biomarkers. The study also
included separate assessments for both genders. Nevertheless, our study has some potential
limitations. Due to the observational and cross-sectional nature of the study and lack of fol-
low-up data it is difficult to derive any causal relationships. The lifestyle factors were self-
reported and thus underreporting and biased recall may occur particularly in the parameters
pertaining to less socially desirable behaviours. The association between the current risk
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factors, the quality of the diet and biomarker responses clearly warrant future studies in large
follow-up materials. Future studies are also needed to examine the effect of lifestyle factors on
indices of inflammation using a wider selection of biomarkers.
Nevertheless, our study demonstrates previously unrecognized relationships between life
style risk factors and biomarker abnormalities, which may prove to be useful in public health
recommendations. The data also suggests a potential for using biomarker-based algorithms in
a comprehensive assessment of interventions aimed at reducing the risks, which based on
recent findings seem to have a major impact on life expectancies and disease outcomes.
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